Risk factor
Very high price volatility
Profitability factor
Very strong margins and returns
About
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers pre-clinical contract research and development services for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, tissue research, assays, molecular pharmacology,...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, of fair value on EV/EBITDA, underv
Target Price
The average target price of GUBRA.CO is 474 and suggests 29% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell